NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $18.37 -0.24 (-1.30%) Closing price 03:59 PM EasternExtended Trading$18.40 +0.03 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunome Stock (NASDAQ:IMNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunome alerts:Sign Up Key Stats Today's Range$18.13▼$19.1950-Day Range$18.58▼$24.6352-Week Range$7.96▼$27.65Volume728,530 shsAverage Volume1.35 million shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice Target$33.17Consensus RatingModerate Buy Company Overview Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles. The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use. Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.AI Generated. May Contain Errors. Read More Immunome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreIMNM MarketRank™: Immunome scored higher than 73% of companies evaluated by MarketBeat, and ranked 185th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingImmunome has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmunome has a consensus price target of $33.17, representing about 81.2% upside from its current price of $18.30.Amount of Analyst CoverageImmunome has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunome's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunome are expected to grow in the coming year, from ($2.06) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.78% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 20.06, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently decreased by 5.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentImmunome has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunome this week, compared to 4 articles on an average week.Search Interest6 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Immunome to their MarketBeat watchlist in the last 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have sold 2,270.78% more of their company's stock than they have bought. Specifically, they have bought $125,050.00 in company stock and sold $2,964,664.00 in company stock.Percentage Held by Insiders7.21% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNM Stock News HeadlinesImmunome: Varegacestat Is The Beachhead, But The ADC Engine Is The ThesisJune 9 at 5:01 AM | seekingalpha.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 | businesswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 9 at 1:00 AM | InvestorPlace (Ad)Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2026 | americanbankingnews.comBarclays Remains a Buy on Immunome (IMNM)June 2, 2026 | theglobeandmail.comImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual MeetingMay 30, 2026 | businesswire.comImmunome (NASDAQ:IMNM) Cut to Sell at Wall Street ZenMay 30, 2026 | americanbankingnews.comInsider Buying: Immunome (NASDAQ:IMNM) Director Buys 5,000 Shares of StockMay 20, 2026 | insidertrades.comSee More Headlines IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $21.48 on January 1st, 2026. Since then, IMNM stock has decreased by 14.8% and is now trading at $18.2990. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.12. When did Immunome IPO? Immunome (IMNM) raised $39 million in an IPO on Thursday, October 1st 2020. The company issued 3,250,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's top institutional investors include Redmile Group LLC (4.91%), Enavate Sciences GP LLC (3.19%), Principal Financial Group Inc. (1.22%) and Readystate Asset Management LP (1.15%). Insiders that own company stock include Isaac Barchas, Clay B Siegall, Philip Wagenheim, Max Rosett, Jean Jacques Bienaime, Philip Tsai, Bruce Turner, Jack Higgins and Robert Lechleider. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunome own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2026Today6/09/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026AGM 20266/09/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IMNM's financial health is in the Green zone, according to TradeSmith. IMNM has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNM CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees40Year Founded2008Price Target and Rating Average Price Target for Immunome$33.17 High Price Target$40.00 Low Price Target$22.00 Potential Upside/Downside+79.1%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.39 million Net MarginsN/A Pretax Margin-5,593.85% Return on Equity-51.15% Return on Assets-47.32% Debt Debt-to-Equity RatioN/A Current Ratio21.68 Quick Ratio21.68 Sales & Book Value Annual Sales$6.94 million Price / Sales302.27 Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book3.22Miscellaneous Outstanding Shares113,250,000Free Float105,085,000Market Cap$2.10 billion OptionableOptionable Beta2.04 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:IMNM) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
